千红制药
(002550)
| 流通市值：45.24亿 | | | 总市值：63.61亿 |
| 流通股本：9.10亿 | | | 总股本：12.80亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,465,941,311.21 | 1,056,756,137.67 | 608,218,905.42 | 2,303,547,790.85 |
| 营业收入 | 1,465,941,311.21 | 1,056,756,137.67 | 608,218,905.42 | 2,303,547,790.85 |
| 二、营业总成本 | 1,300,459,887.27 | 936,630,414.3 | 517,224,547.68 | 1,991,213,922.63 |
| 营业成本 | 836,543,435.77 | 614,967,781.22 | 369,499,426.93 | 1,414,578,909.43 |
| 税金及附加 | 15,081,073.97 | 8,821,950.94 | 5,589,014.8 | 17,101,279.46 |
| 销售费用 | 308,736,457.04 | 217,344,429.03 | 88,286,146.44 | 421,760,640.26 |
| 管理费用 | 93,672,470.7 | 62,822,042.84 | 26,109,178.54 | 123,657,279.44 |
| 研发费用 | 53,171,193.11 | 41,002,111.74 | 20,590,742.37 | 88,311,028.95 |
| 财务费用 | -6,744,743.32 | -8,327,901.47 | 7,150,038.61 | -74,195,214.91 |
| 其中:利息费用 | 5,541,658.84 | 3,908,366.16 | 1,650,620.66 | 5,234,362.95 |
| 其中:利息收入 | 8,187,816.38 | 6,181,428.43 | 4,115,184.82 | 5,642,038.3 |
| 加:公允价值变动收益 | 440,841.65 | 323,896.28 | 166,547.42 | 100,111.03 |
| 加:投资收益 | 3,645,414.5 | 945,072.01 | 282,361.41 | -4,688,793.17 |
| 资产处置收益 | 208.74 | - | - | 57,593,348.38 |
| 资产减值损失(新) | -1,390.24 | -1,390.24 | -1,390.24 | -518,219.71 |
| 信用减值损失(新) | 16,636,515.41 | 8,453,516.1 | 8,205,439.48 | -15,098,739.33 |
| 其他收益 | 8,136,427.17 | 4,836,480.42 | 2,585,065.83 | 10,284,897.22 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 194,339,441.17 | 134,683,297.94 | 102,232,381.64 | 360,006,472.64 |
| 加:营业外收入 | 25,503,374.19 | 141,924.17 | 133,894.42 | 731,231.42 |
| 减:营业外支出 | 1,066,496.32 | 65,202.68 | 10,042.28 | 407,278.75 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 218,776,319.04 | 134,760,019.43 | 102,356,233.78 | 360,330,425.31 |
| 减:所得税费用 | 31,123,994.74 | 21,090,036.45 | 18,806,406.16 | 40,419,598.44 |
| 六、净利润 | 187,652,324.3 | 113,669,982.98 | 83,549,827.62 | 319,910,826.87 |
| 持续经营净利润 | 187,652,324.3 | 113,669,982.98 | 83,549,827.62 | 319,910,826.87 |
| 归属于母公司股东的净利润 | 197,855,106.96 | 119,025,836.94 | 85,946,847.7 | 323,414,382.52 |
| 少数股东损益 | -10,202,782.66 | -5,355,853.96 | -2,397,020.08 | -3,503,555.65 |
| (一)基本每股收益 | 0.15 | 0.09 | 0.07 | 0.25 |
| (二)稀释每股收益 | 0.15 | 0.09 | 0.07 | 0.25 |
| 八、其他综合收益 | -1,565,667.03 | -409,696.28 | -44,827.12 | -2,294,646.62 |
| 归属于母公司股东的其他综合收益 | -1,565,667.03 | -409,696.28 | -44,827.12 | -2,294,646.62 |
| 九、综合收益总额 | 186,086,657.27 | 113,260,286.7 | 83,505,000.5 | 317,616,180.25 |
| 归属于母公司股东的综合收益总额 | 196,289,439.93 | 118,616,140.66 | 85,902,020.58 | 321,119,735.9 |
| 归属于少数股东的综合收益总额 | -10,202,782.66 | -5,355,853.96 | -2,397,020.08 | -3,503,555.65 |
| 公告日期 | 2023-10-25 | 2023-07-22 | 2023-04-15 | 2023-04-15 |
| 审计意见(境内) | | | | 标准无保留意见 |